Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia
- 1 April 2003
- journal article
- research article
- Published by Elsevier in The American Journal of Medicine
- Vol. 114 (6) , 485-494
- https://doi.org/10.1016/s0002-9343(03)00074-3
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Low grade inflammation and coronary heart disease: prospective study and updated meta-analysesBMJ, 2000
- Using Cost-Effectiveness Analysis To Target Cholesterol ReductionAnnals of Internal Medicine, 2000
- C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in WomenNew England Journal of Medicine, 2000
- C-Reactive Protein, a Sensitive Marker of Inflammation, Predicts Future Risk of Coronary Heart Disease in Initially Healthy Middle-Aged MenCirculation, 1999
- Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol LevelsJAMA, 1998
- C-Reactive Protein Adds to the Predictive Value of Total and HDL Cholesterol in Determining Risk of First Myocardial InfarctionCirculation, 1998
- Relationship of C-Reactive Protein to Risk of Cardiovascular Disease in the ElderlyArteriosclerosis, Thrombosis, and Vascular Biology, 1997
- Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy MenNew England Journal of Medicine, 1997
- Relation of C-Reactive Protein and Coronary Heart Disease in the MRFIT Nested Case-Control StudyAmerican Journal of Epidemiology, 1996
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995